U.S. Drug Spending Will Increase 7.6% in 2015, Including PCSK9 Costs – CMS
This article was originally published in The Pink Sheet Daily
Agency expects PCSK9 drugs for cholesterol will have relatively “modest” impact on drug spending across commercial and government payers in 2015, actuaries explain.
You may also be interested in...
Rate of growth in prescription drug spending is expected to average 6.7% per year from 2016 through 2025, National Health Expenditures report from CMS projects.
In the report accompanying FY 2023 HHS appropriations legislation, the House committee also addresses biosimilar uptake in Part D, Medicare dispensing fees for oral COVID-19 drugs and NIH grants for expanded access to investigational ALS drugs.
US legislation attempts to address manufacturer, pharmacy benefit manager impact on patient costs in addition to health plan benefit designs. Critics suggest it’s too easy on manufacturers but that may help its chances with Republicans.